MDGN Key Stats
- Medgenics, Inc. to Present at the 26th Annual ROTH Capital Growth Conference noodls 03/05 09:46 ET
- Medgenics Reports 2013 Financial Results noodls 02/20 10:15 ET
- MEDGENICS, INC. Files SEC form 10-K, Annual Report Yahoo 02/20 08:16 ET
- Medgenics Issues Stock Options and Restricted Shares to Non-Executive Directors noodls 01/07 13:52 ET
- Medgenics Announces Director Enters into Stock Trading Plan and Change of Adviser noodls 12/24 07:48 ET
- Medgenics Reports Open Market Purchase of Common Stock by Director noodls 12/18 09:26 ET
- VP exec raises stake after first-half results 12/16 11:56 ET
- Medgenics reports open market purchase of stock by chairman 12/16 09:05 ET
- Medgenics Reports Open Market Purchase of Common Stock by Chairman of the Board Business Wire 12/16 09:00 ET
- Medgenics Becomes Oversold (MDGN) The Street 12/13 11:21 ET
|Apr 28||Misc||AGM Event for Medgenics Inc|
MDGN Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Medgenics is up 74.95% over the last year vs S&P 500 Total Return up 24.21%, ARCA biopharma down 14.61%, and Xencor up N/A.
Balance Sheet View Statement
Pro Ratings for MDGN
Pro Strategies Featuring MDGN
Did Medgenics make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters Country: United States
- Headquarters State/Province: Pennsylvania
- Incorporation Country: United States
- Incorporation State/Province: Delaware
Medgenics Inc is a medical technology and therapeutics company. The Company and its subsidiary are engaged in the research and development of products in the field of biotechnology and associated medical equipment.